Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.44%198.251.2%$509.50m
GILDGilead Sciences, Inc.
0.10%73.660.9%$447.48m
BIIBBiogen Inc.
0.09%331.251.3%$368.94m
CELGCelgene Corporation
0.11%82.671.2%$330.81m
ILMNIllumina, Inc.
-1.01%318.463.5%$287.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.94%380.572.6%$221.85m
ALXNAlexion Pharmaceuticals, Inc.
0.83%122.952.0%$210.47m
VRTXVertex Pharmaceuticals Incorporated
-0.75%179.971.9%$201.97m
SRPTSarepta Therapeutics, Inc.
2.19%133.3616.4%$170.07m
AAgilent Technologies, Inc.
-0.02%66.231.5%$154.52m
BMRNBioMarin Pharmaceutical Inc.
0.80%100.314.4%$129.38m
VKTXViking Therapeutics, Inc.
-1.04%14.310.9%$107.63m
LGNDLigand Pharmaceuticals Incorporated
-1.28%200.0023.3%$106.76m
NKTRNektar Therapeutics
1.06%49.435.6%$106.59m
NBIXNeurocrine Biosciences, Inc.
-0.40%111.045.1%$96.59m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.